OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, March 13, 2012

Bloomberg News: Canadian Hospitals That Spend More on Patients Get More - Businessweek



Canadian Hospitals That Spend More on Patients Get More - Businessweek

Bloomberg News

Canadian Hospitals That Spend More on Patients Get More

By Drew Armstrong on March 13, 2012
Canadian hospitals that spent the most on patient care may be getting a bigger bang for their buck than their U.S. counterparts, researchers suggested.
A study reported today in the Journal of the American Medical Association compared patient results between Canadian hospitals that spent more on care, and those that spent less. It found patients in the first category had lower death rates and were less likely to be admitted to intensive care.
Research on the U.S. health-care system, however, has shown that higher spending at hospital systems doesn’t guarantee better results, according to the study’s author, Therese Stukel.
“When we spend more, and when we place these specialized resources, we’re doing it in an efficient way,” said Stukel, a senior scientist at the Institute for Clinical Evaluative Sciences in Toronto, in a telephone interview. “That’s in contrast to the U.S.”
Under Canada’s system of universal health care, patients at high-spend hospitals had longer lengths of stay and more specialist visits, the study found. That’s because the health plan in Canada, where per capita health expenditures are 57 percent of those in the U.S., better allocates expensive specialists and technology, Stukel said.
While the U.S. has a 3- to 4-times higher per capita supply of expensive, specialized technology, such as MRIs, it has a similar supply of hospital beds and nurses as Canadian hospitals, according to the study.

Dartmouth Atlas

The Canadian findings may help to better understand studies such as the Dartmouth Atlas of Healthcare, a 20-year research project that has documented variations in how medical resources are distributed in the U.S. The data has shown that the parts of the country that spent the most per patient have worse patient outcomes than low-spending areas.
Today’s study “breaks through the generalization,” that all spending is bad, said David Goodwin, co-principal investigator at the Dartmouth Atlas, in a telephone interview. “It’s important that we look at spending in the aggregate and where more is better, and where more is worse.”
The U.S. health-care law signed in 2010 has several components designed to slow spending and have U.S. hospitals emulate the coordinated care of their Canadian brethren. Those measures haven’t been without controversy. Republicans are seeking to repeal the law’s Independent Payment Advisory Board, which will cut Medicare rates with limited oversight from lawmakers.
The law’s Accountable Care Organizations have Medicare pay hospitals bonuses when they coordinate to provide better care and save money. Health systems are penalized if they overspend or produce worse outcomes.

Misinterpreting Dartmouth

In an editorial accompanying the research, Karen Joynt and Ashish Jha, researchers at the Harvard School of Public Health, said some policymakers have drawn wrong conclusions from the Dartmouth data.
“What Dartmouth investigators have documented through careful work is that dysfunctional systems produce expensive, poor-quality care,” Joynt and Jha wrote.
Stukel’s Canadian study examined nearly 400,000 cases of heart attack, heart failure, hip fracture and colon cancer in Ontario hospitals over 10 years, looking at whether the patients died or were readmitted.
The most expensive Canadian hospitals in the study spent about twice as much per patient than their lower-spending counterparts. For every condition the study looked at, patients died less often and were readmitted less often at the more expensive hospitals.

Expensive Hospitals

Those more expensive hospitals had something else in common -- they were often academic hospitals, or community hospitals that saw more patients than others, they had cancer centers attached, lots of specialists on staff, performed more advanced procedures, had more technology and nurses that spent more time with patients. Patients were also more likely to get a follow-up visit within a year and get more intensive discharge care.
That’s not to say that putting more money into lower- spending Canadian hospitals would produce better care there.
“It would be facile to interpret this study as demonstrating that higher spending is causally related to better outcomes and providing more money to lower spending hospitals would necessarily improve their outcomes,” Stukel and her co- authors said in the study.
Instead, it’s better care coordination and spending on the right types of care that improve outcomes, as well as limited budgets on overall spending, Stukel said.

Coordinated Systems

Stukel said she doesn’t advocate a Canadian-style system of universal coverage in the U.S. She said that coordinated U.S. managed care systems, like Kaiser Permanente in California, Intermountain Healthcare in Salt Lake City, and Geisinger Health System in Pennsylvania are models the rest of the country emulate.
She predicts that Canadian hospitals will likely use her study to ask the government there for more money, even though that’s not the point of her research.
“If we put more dollars into the acute care system, it might still improve, it might peak,” she said. “It’s not just putting money into the system, it’s where we spend it.”

Comments needed - exp March 15th - Patients: Your Researcher Will See You Now!--Kathleen O'Malley



 CLICK HERE TO SUBMIT COMMENTS to PCORI.

Patients: Your Researcher Will See You Now!--Kathleen O'Malley:

Guest blogger Susan Woods, a physician and SPM board member, urges patients to help shape PCORI’s draft National Priorities for Research and initial Research Agenda, and offers her own comments here. The public comment period ends at 11:59 pm EST on March 15.

Patient voices are needed now!

The Patient Centered Outcomes Research Institute (PCORI) is soliciting input about patient-centered outcomes research. We blogged about this when they were seeking people to apply to be participants.

           Now the deadline to submit your comments is almost here.

PCORI is an independent, non-profit organization established by Congress through the 2010 Patient Protection and Affordable Care Act. Its mission is to help people make informed health care decisions by producing and promoting high integrity, evidence-based information that comes from research guided by patients, caregivers, and the broader health care community.
The legislation creating this group, governed by a 21-member board, is fascinating. Patient advocates must be part of the process: “For identifying research priorities, they take into account…a number of factors including variations and health disparities, the potential for new evidence to improve patient health, well-being, and the quality of care…as well as patient needs, outcomes, and preferences, the relevance to patients and clinicians in making informed health decisions….”
This is enlightenment in medical research. The law also states:
“All funded studies will have a strong orientation to the patient perspective and all will have patients involved in the development of the research, its governance and oversight, and its dissemination strategy.”

Editorial: The Relationship Between Cost and Quality, No Free Lunch - March 14, 2012 — JAMA + link to original article



The Relationship Between Cost and Quality, March 14, 2012, Joynt and Jha 307 (10): 1082 — JAMA
 Editorial: The Relationship Between Cost and Quality 
No Free Lunch

Since this article does not have an abstract, we have provided the first 150 words of the full text. (Blogger's Note: subscription required to view $$$)
"For the past 30 years, research from investigators at Dartmouth has demonstrated large and persistent variations in costs and quality across the US health care system. Beyond simply showing that cost and quality vary by geography, the Dartmouth Atlas has demonstrated that in many communities, care is so fragmented and ineffective that greater spending on Medicare beneficiaries often leads to worse outcomes1,2 because some patients receive services that are redundant and low value and that may even have substantial risks. 

However, some US policy makers have misinterpreted the Dartmouth research and in the troves of data have found what they believe to be a free lunch: given the inverse relationship between costs and quality, it follows that it should be possible to simultaneously reduce spending and improve care. Although this notion is attractive, much of the subtlety of the Dartmouth work has been lost in translation. What ....."


Related article

YouTube: Interview with Dr Stukel, Author of Hospital Spending Intensity and Patient Outcomes




Also, planning a comparison study with London School of Economics and Havard

open access: Association of Hospital Spending Intensity With Mortality and Readmission Rates in Ontario (Canada) Hospitals, March 14, 2012 — JAMA



 Blogger's Note: universal healthcare system, this study included colorectal cancer patients, comparisons between Canadian/U.S. systems, note authors' affiliations

Association of Hospital Spending Intensity With Mortality and Readmission Rates in Ontario Hospitals, March 14, 2012

"Our objective was to assess whether acute care patients admitted to Canadian hospitals that treat patients more intensively (and at higher cost) have lower mortality and readmissions and higher quality of care.......We studied 4 common conditions that have moderate to high incidence and mortality, that can be validly ascertained using health administrative data, and for which treatment follows relatively standard protocols. "

Design Overview

We undertook a longitudinal cohort study of patients hospitalized with selected acute clinical conditions in Ontario, Canada, and assessed the content, quality, and outcomes with respect to “exposure” to the index hospital's medical spending intensity. Medical intensity is defined as the quantity of medical care provided overall to similarly ill patients and is a marker of a hospital's propensity to treat similarly ill patients more (or less) intensively. It reflects the component of spending variation attributable to practice style rather than to differences in illness or price.
Because sicker patients use more services, higher-spending hospitals may appear to have worse outcomes, in part because patients are more severely ill. We used several techniques to remove this potential “reverse causality,” as in previous work.1,2​,3,4

 COMMENT

We found that higher hospital spending intensity was associated with better survival, lower readmission rates, and better quality of care for seriously ill, hospitalized patients in Ontario in a universal health care system with more selective access to medical technology. Higher-spending hospitals were higher-volume teaching or community hospitals with high-volume or specialist attending physicians and having specialized programs, such as regional cancer centers, and specialized services, such as on-site cardiac catheterization, cardiac surgery, and diagnostic imaging facilities. The study also points to plausible mechanisms through which higher spending may be associated with better outcomes. 

Benefits appeared early, suggesting an acute-phase hospital effect. For acute conditions, timely access to preoperative and in-hospital specialist care, skilled nursing staff, rapid response teams, cardiac high-technology services, and regional cancer centers, all found in the higher-spending systems, are related to better outcomes.21​,27,34​,35,36​,37,38​,39 These systems also provided consistently, but not strikingly, higher levels of evidence-based care and collaborative ambulatory care, both shown to improve care.22​,23,40 Higher spending on evidence-based services delivered in the acute phase of care for severely ill hospitalized patients—by far the largest component of spending for our cohorts—is indeed likely to be beneficial. 

It would be facile to interpret this study as demonstrating that higher spending is causally related to better outcomes and that providing more money to lower-spending hospitals would necessarily improve their outcomes. Higher-spending hospitals differed in many ways, such as greater use of evidence-based care, skilled nursing and critical care staff, more intensive inpatient specialist services, and high technology, all of which are more expensive. 

To place the study in context, the United States has a 3- to 4-times higher per capita supply of specialized technology, such as computed tomography and magnetic resonance imaging scanners, but a similar supply of acute care beds and nurses.41 Ontario 2001 population rates of cardiac testing and revascularization lagged behind corresponding 1992 US rates and paralleled the supply of cardiologists and catheterization facilities.42​,43,44 It is therefore possible that Canadian hospitals, with fewer specialized resources, selective access to medical technology, and global budgets, are using these resources more efficiently, especially during the inpatient episode for care-sensitive conditions.45,46 Canada's health care expenditures per capita are about 57% of those in the United States.47 At this spending level, there might still be a positive association between spending and outcomes. For example, the same-day PCI rate for patients with AMI in low-intensity hospitals in 2008 was 3.5%, leaving room for improvement. This pattern is consistent with studies in the United States showing a positive association between spending and outcomes among low-intensity hospitals or regions but no association at average or higher intensity levels.5​,6

Strengths of the study include the population-based, longitudinal cohort design; the consistency of findings across cardiac, cancer, medical, and surgical patients; the examination of plausible clinical mechanisms whereby higher intensity may be associated with better outcomes; and the examination of readmissions. The “look-back” (EOL-EI) and “look-forward” (AC-EI) measures of spending intensity were highly correlated and produced similar findings, as in US studies.2
 ​
Several limitations should be considered. Because the design precludes strong inferences about causation, we cannot know which components of care may have led to better outcomes. In observational studies, comparisons of exposure groups may be biased because of unobserved selection bias.13 It is unlikely that the findings are the result of unmeasured case mix, because patients in higher-spending hospitals had similar or higher illness severity at admission, which would, if anything, bias toward finding worse outcomes. We cannot rule out the possibility that higher-intensity hospitals coded more aggressively, but there is less incentive to do so in a system with global hospital budgets. Although admission severity would be determined more accurately using clinical detail from medical charts, previous work has shown high concordance between risk-adjusted hospital outcomes using chart and administrative data.48​,49 Canadian data distinguish between comorbidities present at admission and complications, leading to improved admission severity coding. The EOL-EI has been critiqued for the purpose of estimating hospital efficiency50​,51 but is used here simply to distinguish high- and low-intensity hospitals, as in other US studies.1​,2,3​,4 The findings may not generalize to chronic conditions, for which avoiding exacerbations of disease that lead to hospitalization through coordinated ambulatory care is key. The findings also may not generalize to jurisdictions in which hospital resources are more abundant and are used in cost-effective as well as cost-ineffective ways, leading to inefficiency.45​,46

This study shows that in Ontario, a province with global hospital budgets and fewer specialized health care resources than the United States, outcomes following an acute hospitalization are positively associated with higher hospital spending intensity. Higher spending intensity, in turn, is associated with greater use of specialists, better patient care, and more use of advanced procedures. These results suggest that it is critical to understand not simply how much money is spent but whether it is spent on effective procedures and services. 

pdf file: 

http://jama.ama-assn.org/content/307/10/1037.full.pdf




open access: PLoS Medicine: A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem Persists



PLoS Medicine: A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem Persists

 Introduction

All medical subspecialties have been subject to increased scrutiny about the ways by which their financial associations with industry, such as pharmaceutical companies, may influence, or give the appearance of influencing, recommendations in review articles [1] and clinical practice guidelines [2]. Psychiatry has been at the epicenter of these concerns, in part because of high-profile cases involving ghostwriting [3],[4] and failure to report industry-related income [5], and studies highlighting conflicts of interest in promoting psychotropic drugs [6],[7]. The revised Diagnostic and Statistical Manual of Mental Disorders (DSM), scheduled for publication in May 2013 by the American Psychiatric Association (APA), has created a firestorm of controversy because of questions about undue industry influence. Some have questioned whether the inclusion of new disorders (e.g., Attenuated Psychotic Risk Syndrome) and widening of the boundaries of current disorders (e.g., Adjustment Disorder Related to Bereavement) reflects corporate interests [8],[9]. These concerns have been raised because the nomenclature, criteria, and standardization of psychiatric disorders codified in the DSM have a large public impact in a diverse set of areas ranging from insurance claims to jurisprudence. Moreover, through its relationship to the International Classification of Diseases [10], the system used for classification by many countries around the world, the DSM has a global reach.........

Summary Points

  • The American Psychiatric Association (APA) instituted a financial conflict of interest disclosure policy for the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM).
  • The new disclosure policy has not been accompanied by a reduction in the financial conflicts of interest of DSM panel members.
  • Transparency alone cannot mitigate the potential for bias and is an insufficient solution for protecting the integrity of the revision process.
  • Gaps in APA's disclosure policy are identified and recommendations for more stringent safeguards are offered.

Stop the Multivitamin Madness - Cancerwise | Cancer blog from MD Anderson Cancer Center



Stop the Multivitamin Madness - Cancerwise | Cancer blog from MD Anderson Cancer Center

Drug Shortages > Current Drug Shortages - Ondansetron Injection 2 mg/mL



Drug Shortages > Current Drug Shortages

Disruptive Women in Health Care » Blog Archive » What Does It Matter to You: Patient Activation and Good Health Outcomes (on attitudes, knowledge, communication and abuse??)



Disruptive Women in Health Care » Blog Archive » What Does It Matter to You: Patient Activation and Good Health Outcomes

Social Networking Sites and Politics - Pew Research Center



Social Networking Sites and Politics - Pew Research Center
 
Postings on social networking sites reveal surprises for many users when it comes to the political views of their friends. Nearly four-in-ten users discovered through postings by friends that their political beliefs were different than they thought. A small percentage of users blocked, unfriended or hidden someone on the site because their postings were too frequent or they disagreed with them.
Three-quarters of social networking site users say their friends post at least some content related to politics on the sites from time to time. They amount to 40% of the entire adult population.
For some users politics is an off-limits subject. Some 22% of SNS users say they have decided not to post political comments or links to political material because they were worried it might upset or offend someone.
Read the full report which includes:
  • Users' responses by partisan affiliation and ideology
  • How users have responded to political content they do not like
  • Frequency of agreement and disagreement among "friends"

open access: Children and young adults with parents with cancer: a population-based study



Children and young adults with parents with cancer: a population-based study

Background: 
Today many people are choosing to have children later in life. Additionally, the use of sophisticated diagnostic tools and screening modalities has increased over recent years. Because of these factors, cancer is being diagnosed more frequently during the child-rearing years. Sociodemographic and cancer-related information on families and minor (0–18 years) and young adult (YA) (19–25 years) children experiencing parental cancer is scarce, but this information is vital for healthcare initiatives aimed toward those potentially adversely affected. Therefore, the aim of this study was to describe features of families and minor and YA children affected by parental cancer in a nationwide population.
  
Conclusion: 
Adequate assistance for minor and YA children affected by parental cancer requires knowledge of their number and characteristics. Parental cancer is more common than previously suggested: the annual incidence of parental cancer for children under 18 years of age is 0.3%, whereas approximately 4% of children aged 0–25 years have or have had parents diagnosed with cancer, corresponding to a population prevalence of 1.4%. Around 20% of these children experience parental death, and surveys of live respondents should account for this.

abstract: Management and prognosis of endometrioid borderline tumors of the ovary



Management and prognosis of endometrioid borderline tumors of the ovary
Source: Surgical Oncology

Background 
The Endometrioid Borderline ovarian tumor (EBOT) is the third most common histological subtype of borderline ovarian tumors. Very little is known about the prognosis and management of this entity. This paper consists of a review of the literature and an analysis of clinical series.

Study design 
A review of the literature on this topic was conducted identifying series reporting consecutive cases of EBOT using 2 search engines (MEDLINE and Pubmed). Personal data on this topic have been included and concern a series of patients treated between 1985 and 2009 for EBOT. These cases included in this series had complete data concerning patient management and follow-up >12 months.

Results 
16 patients were studied: 7 had been treated conservatively and 9 radically. All 16/16 patients had stage I disease at the initial diagnosis but one patient had also developed synchronous endometrioid adenocarcinoma of the uterine corpus. After a median time of 24 months (range, 12–132) post treatment, one (1/16) patient had developed two recurrences. She remains disease-free 42 months after the end of treatment of the last recurrence. These data were compared to the results of 4 series previously reported in the literature. In fact, the present series reports on the first recurrence in EBOT (which was an invasive lesion).

Conclusion 
Endometrioid borderline ovarian tumors carry a good prognosis. Most EBOT tumors are stage I, therefore surgical staging is not necessary in most of the cases. However, uterine curettage is required in cases of uterine preservation.

open access: JCO Editorial: Palliative Sedation: When and How?




 Palliative Sedation: When and How?

".....As with many other medical interventions, the controversy that
surrounds palliative sedation is not linked to the question of “yes or
no?” but rather, “when and how?”"

abstract and podcast: Palliative Sedation in End-of-Life Care and Survival: A Systematic Review [Palliative and Supportive Care] (unbearable suffering)



 Blogger's Note: search blog for other articles regarding palliative sedation

 
Palliative Sedation in End-of-Life Care and Survival: A Systematic Review [Palliative and Supportive Care]:

Purpose
Palliative sedation is a clinical procedure aimed at relieving refractory symptoms in patients with advanced cancer. It has been suggested that sedative drugs may shorten life, but few studies exist comparing the survival of sedated and nonsedated patients. We present a systematic review of literature on the clinical practice of palliative sedation to assess the effect, if any, on survival.

 Conclusion
Even if there is no direct evidence from randomized clinical trials, palliative sedation, when appropriately indicated and correctly used to relieve unbearable suffering, does not seem to have any detrimental effect on survival of patients with terminal cancer. In this setting, palliative sedation is a medical intervention that must be considered as part of a continuum of palliative care.
  
                            ~~~~~~~~~~~~~~~~~~~~~~~~

Users can play the podcast directly in the audio player embedded below. If Flash is disabled on your browser, you can save the file directly to your computer or open on your mobile device by clicking on "download file."

Sedation for the Management of Refractory Suffering
by Nathan Cherny


(Download file - duration 0:10:41, file size 9.80 MB)
This podcast presenter indicated no conflicts of interest.


abstract: Web-Based Tailored Education Program for Disease-Free Cancer Survivors With Cancer-Related Fatigue: A Randomized Controlled Trial



Web-Based Tailored Education Program for Disease-Free Cancer Survivors With Cancer-Related Fatigue: A Randomized Controlled Trial
  
Abstract
Purpose 
To determine whether an Internet-based tailored education program is effective for disease-free cancer survivors with cancer-related fatigue (CRF). 

Conclusion 
An Internet-based education program based on NCCN guidelines and TTM may help patients manage CRF.


JCO Letter: Is It Possible to Identify Clinically Useful Prognostic Groups for Patients With Desmoid Tumors




Is It Possible to Identify Clinically Useful Prognostic Groups for Patients
With Desmoid Tumors

 TO THE EDITOR: 

In their recent article, Salas et al1 report the results of a retrospective study of 426 patients with extra-abdominal desmoid tumors from 24 participating centers.Toour knowledge, this is the largest such cohort ever reported. Three hundred seventy patients (86.9%) had surgical treatment initially; a wait-and-see policy was adopted for only 27 patients (6.3%). Patients who had non–lifethreatening tumors or who were at risk for mutilation were selected for the wait-and-see approach. Detailed characteristics of the patients in the wait-and-see group were not provided. Factors that had a significant impact on progression-free survival were age, tumor size, and tumor site in multivariate analysis. It can be understood that there are different prognostic subgroups of patients with desmoid tumors who could benefit from different therapeutic strategies...."

Salas S, Dufresne A, Bui B, et al: Prognostic factors influencing progressionfree survival determined from a series of sporadic desmoid tumors: A wait-andsee policy according to tumor presentation. J Clin Oncol 29:3553-3558, 2011

JCO Letter: Is It Possible to Identify Clinically Useful Prognostic Groups for Patients With Desmoid Tumors



JCO.2011.39.8636.full.pdf (application/pdf Object)

"TO THE EDITOR:
In their recent article, Salas et al1 report the results of a retrospective study of 426 patients with extra-abdominal desmoid tumors from 24 participating centers.Toour knowledge, this is the largest such cohort ever reported. Three hundred seventy patients (86.9%) had surgical treatment initially; a wait-and-see policy was adopted for only 27 patients (6.3%). Patients who had non–lifethreatening tumors or who were at risk for mutilation were selected for the wait-and-see approach. Detailed characteristics of the patients in the wait-and-see group were not provided........."

abstract: Psychosocial Care for Family Caregivers of Patients With Cancer [Review Articles]



Psychosocial Care for Family Caregivers of Patients With Cancer [Review Articles]:

Purpose
To understand family caregivers' needs for better preparation and care, this state-of-the-science review examines the effect of caregiving on the health and well-being of caregivers, the efficacy of research-tested interventions on patient and caregiver outcomes, implications of the research on policy and practice, and recommendations for practice and future research.

Methods
We reviewed research that described the multiple effects of cancer on caregivers' well-being. Five meta-analyses were analyzed to determine the effect of interventions with caregivers on patient and caregiver outcomes. In addition, we reviewed legislation such as the Affordable Care Act and the Family Leave Act along with current primary care practice to determine whether family caregivers' needs have been addressed.

abstract: Oncologist Burnout: Causes, Consequences, and Responses



Oncologist Burnout: Causes, Consequences, and Responses

 Abstract
"Although the practice of oncology can be extremely rewarding, it is also one of the most demanding and stressful areas of medicine. Oncologists are faced with life and death decisions on a daily basis, administer incredibly toxic therapies with narrow therapeutic windows, must keep up with the rapid pace of scientific and treatment advances, and continually walk a fine line between providing palliation and administering treatments that lead to excess toxicity. Personal distress precipitated by such work-related stress may manifest in a variety of ways including depression, anxiety, fatigue, and low mental quality of life. Burnout also seems to be one of the most common manifestations of distress among physicians, with studies suggesting a prevalence of 35% among medical oncologists, 38% among radiation oncologists, and 28% to 36% among surgical oncologists. Substantial evidence suggests that burnout can impact quality of care in a variety of ways and has potentially profound personal implications for physicians including suicidal ideation. In this review, we examine the causes, consequences, and personal ramifications of oncologist burnout and explore the steps oncologists can take to promote personal well-being and professional satisfaction."

abstract: Communication Skills Training for Oncology Professionals



Communication Skills Training for Oncology Professionals

 Conclusion

"Future communication challenges include genetic risk communication, concepts like watchful waiting, cumulative radiation risk, late effects of treatment, discussing Internet information and unproven therapies, phase I trial enrollment, and working as a multidisciplinary team. Patient benefits, such as increased treatment adherence and enhanced adaptation, need to be demonstrated from CST."

abstract: (review of the literature) Screening for Distress and Unmet Needs in Patients With Cancer: Review and Recommendations



Screening for Distress and Unmet Needs in Patients With Cancer: Review and Recommendations

"....Many distress screening and unmet need tools have been subject to preliminary validation, but few have been compared head to head in independent centers and in different stages of cancer...."

abstract: Psychosocial Care of Adolescent and Young Adult Patients With Cancer and Survivors



Psychosocial Care of Adolescent and Young Adult Patients With Cancer and Survivors

JCO - Editorial: Caring for the Whole Patient: The Science of Psychosocial Care



open access: Editorial (special series) Caring for the Whole Patient: The Science of Psychosocial Care

"This Journal of Clinical Oncology Special Series relates to the
science of psychosocial care. This series is designed to provide oncology
professionals with the most recent information about the psychological,
psychiatric, and social aspects of cancer care. The emergence of
the field of psychosocial care reflects growing public and professional
awareness of the potential for cancer and its treatment to have profound
effects on many aspects of life. A principal goal of psychosocial
care is to recognizeandaddress the effects that cancerandits treatment
have on the mental status and emotional well-being of patients, their
family members, and their professional caregivers....."

JCO - open access: Editorial - Financial Hardship: A Consequence of Survivorship?



Financial Hardship: A Consequence of Survivorship?


"Despite this success on the treatment front, we have done
little in a concerted and well-planned fashion to investigate
and address the problems of survivors. It is as if we have
invented sophisticated techniques to save people from
drowning, but once they have been pulled from the water,
we leave them on the dock to cough and splutter on their
own in the belief that we have done all that we can."

—Fitzhugh Mullan, MD, physician, survivor of cancer, and
founding president of the National Coalition for Cancer
Survivorship

Monday, March 12, 2012

open access: Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women (comparison to CA-125)



Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer

Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women

Journal of Translational Medicine 2012, 10:45 doi:10.1186/1479-5876-10-45

Publication date 12 March 2012
Article URL http://www.translational-medicine.com/content/10/1/45

"The study population comprised 244 apparently healthy normal women, 223 patients with benign gynecological conditions, 53 patients with borderline ovarian tumours and 222 patients with malignant ovarian tumours (serous, mucinous, endometrioid, clear cell, other)  (Table 1)."

"The malignant ovarian cancer cohort comprised 130 (58.5%) serous, 19 (8.6%)endometrioid, 16 (7.2%) mucinous, 16 (7.2%) clear cell and 41 (18.5%) of other types that included predominantly mixed forms and adenocarcinomas with no specific histotype recorded (Table 1). A total of 33 (14.9%) of malignant ovarian cancer samples had no staging data reported, 42 (18.9%) were diagnosed with Stage I disease, 27 (12.2%) with Stage II, 106 (47.7%) Stage III and 14 (6.3%) with Stage IV disease (Table 1)."

"Of the ovarian malignancies, 88.5% of all serous tumours, 57.9% of all endometrioid tumours, 62.5% of all mucinous tumours, 81.2% of all clear cell tumours and 85.4% of other epithelial ovarian cancer plasma samples were correctly identified (Table 5). The IVDMIA correctly predicted 91.7% of the late stage (Stages III-IV) samples, and 69.6% of the early stage (Stages I-II) malignant ovarian cancer samples (Table 5).

Conclusions
This study confirms in an independent sample set that a blood-based multianalyte assay has significant advantages over CA125 for distinguishing symptomatic women with borderline and malignant ovarian cancer from controls or those with benign disease.

Competing interests
This study was funded as part of the research and development activities of Healthlinx Ltd. DJA, LR, KK and KB are employees of Healthlinx Ltd and GER is non-executive chairman of Healthlinx Ltd. DJA is an inventor on patent applications that are related to the current
study.

Keywords
Ovarian cancer, Tumour markers, Multianalyte, Diagnostic
Background

phase 11/111 - Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov



Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov

Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This study is currently recruiting participants.
Verified March 2012 by NCIC Clinical Trials Group

First Received on October 9, 2009.   Last Updated on March 9, 2012   History of Changes
Sponsor: NCIC Clinical Trials Group
Collaborators: National Cancer Institute (NCI)
Grupo Español de Investigación en Cáncer de Ovario
Cancer Research UK
Southwestern Oncology Group (SWOG)
Information provided by (Responsible Party): NCIC Clinical Trials Group
ClinicalTrials.gov Identifier: NCT00993655
  Purpose
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube cancer.
PURPOSE: This randomized phase II/III trial is comparing the side effects of three combination chemotherapy regimens and to see how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.

Condition Intervention Phase
Fallopian Tube Cancer
Metastatic Cancer
Ovarian Cancer
Peritoneal Cavity Cancer
Drug: carboplatin
Drug: cisplatin
Drug: paclitaxel
Procedure: quality-of-life assessment
Phase II
Phase III

Phase 1 - TKM 080301 for Primary or Secondary Liver Cancer - Full Text View - ClinicalTrials.gov (ovariancolorectal/pancreas/gastric (stomach)/breast)



TKM 080301 for Primary or Secondary Liver Cancer - Full Text View - ClinicalTrials.gov

Colorectal Cancer With Hepatic Metastases
Pancreas Cancer With Hepatic Metastase
Gastric Cancer With Hepatic Metastase
Breast Cancer With Hepatic Metastase
Ovarian Cancer With Hepatic Metastase
TKM 080301 for Primary or Secondary Liver Cancer
This study is currently recruiting participants.
Verified February 2012 by National Institutes of Health Clinical Center (CC)

First Received on September 16, 2011.   Last Updated on March 9, 2012   History of Changes
Sponsor: National Cancer Institute (NCI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT01437007
  Purpose
Background:
Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g. colon, pancreas, gastric, breast, ovarian, esophageal cancers, cancer with metastases to the liver.) People who have tumors that can be removed by surgery live longer than those whose cancer cannot be removed. Chemotherapy can shrink some tumors in the liver, which also helps people to live longer, and sometimes chemotherapy can shrink tumors enough that they can be removed by surgery. However, most chemotherapy drugs do not work well on tumors in the liver. In this study we are testing a new drug, TKM-080301, given directly into the cancer blood supply in the liver circulation, to see if it will cause tumors to shrink.
Objectives:
- To test the safety and effectiveness of TKM-080301 for cancer in the liver that has not responded to standard treatments.

Beta-Blocker / Ovarian - Full Text View - ClinicalTrials.gov




Beta-Blocker / Ovarian - Full Text View - ClinicalTrials.gov

Beta-Blocker / Ovarian
This study is currently recruiting participants.
Verified March 2012 by M.D. Anderson Cancer Center

First Received on January 3, 2012.   Last Updated on March 9, 2012   History of Changes
Sponsor: M.D. Anderson Cancer Center
Information provided by (Responsible Party): M.D. Anderson Cancer Center ( M.D. Anderson Cancer Center )
ClinicalTrials.gov Identifier: NCT01504126
  Purpose
The goal of this clinical research study is to learn if it is feasible to give a beta-blocker such as Inderal (propranolol hydrochloride) with standard chemotherapy (paclitaxel and carboplatin or possibly docetaxel) to treat ovarian cancer. The safety of propranolol hydrochloride will also be studied.
Propranolol hydrochloride is designed to block certain chemicals that affect the heart. Researchers want to learn if this might also boost the immune system, allowing the chemotherapy to be more effective.
Paclitaxel is designed to block cancer cells from dividing, which may cause them to die.
Carboplatin is designed to interfere with the growth of cancer cells by stopping cell division, which may cause the cells to die.

Lymphedema: Separating Fact From Fiction - Cancer Network



Lymphedema: Separating Fact From Fiction - Cancer Network

"..... Recently, Cormier et al found only 47 studies between 1972 and 2008 with more than 10 patients that prospectively evaluated lymphedema as a primary or secondary outcome after treatment for melanoma, bladder, sarcoma, penile, prostate, vulvar, cervical, endometrial, or head and neck cancers.[2] The authors’ analysis of these studies demonstrated the overall incidence of lymphedema to be 16.3% after melanoma, 10.1% after genitourinary cancers, and 19.6% after gynecologic malignancies, and notes that lymphedema rates are higher when the lower rather than upper extremity is affected. Given the abundance of breast cancer data, this review will focus on breast cancer–related lymphedema. However, the principles and controversies discussed are relevant regardless of the type of malignancy to which the lymphedema is attributed....."

Association of Patient-Centered Outcomes With Patient-Reported and ICD-9–Based Morbidity Measures



Association of Patient-Centered Outcomes With Patient-Reported and ICD-9–Based Morbidity Measures

CONCLUSIONS
"A comprehensive assessment of morbidity requires both subjective and objective measurement of disease burden as well as an assessment of emotional symptoms. Such multidimensional morbidity measurement is particularly relevant for research or quality assessments involving the delivery of patient-centered care to complex patient populations."

open access: (Canada) How the Medical Culture Contributes to Coworker-Perpetrated Harassment and Abuse of Family Physicians (includes patients, families, education system, co-workers)



How the Medical Culture Contributes to Coworker-Perpetrated Harassment and Abuse of Family Physicians


"At present, little is being undertaken to address the issue of abuse in the workplace of family physicians. The most worrisome finding from our study is that these kinds of practices are a part of the medical culture starting in medical school and carried out throughout medical training and into the work environment. This culture is supported by power imbalances, power structures, and such systemic issues as physician shortages. The criminological broken window theory is helpful to explain why abuse may be perpetuated in the medical system, and it also provides a context for an approach to address the issue."

Elderly Frequently 'Undertriaged' in Emergency Departments



Elderly Frequently 'Undertriaged' in Emergency Departments

"Finally, the authors investigated reasons for inadequate triage. The most common reason for undertriage was neglect of high-risk situations, sometimes in combination with abnormal vital signs or in combination with severe pain or distress.
The second most important reason for undertriage was inappropriate interpretation of vital signs, sometimes in combination with severe pain or distress, high-risk situations, or an altered mental status.
"[I]nadequate triage appears to be due to a lack of adherence to the Emergency Severity Index algorithm rather than to an inherent deficit of the algorithm itself," the researchers conclude."


Ann Emerg Med. Published online March 9, 2012. Abstract
Conclusion
"In our study, older patients were at risk for undertriage. However, our results suggest that the Emergency Severity Index is reliable and valid for triage of older patients."

MD News - HIPEC: Furthering Survivorship for GYN Cancer Patients



MD News - HIPEC: Furthering Survivorship for GYN Cancer Patients



A team of cancer specialists at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center is among the first in the nation to launch a dedicated gynecologic program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other malignancies.





 Q: What is HIPEC, and how is it delivered?
Q: What are the advantages of HIPEC over traditional IV chemotherapy?
Q: I understand UH is planning several research studies on HIPEC. What will they involve?
Q: What do you want physicians to know about HIPEC?
   

Blogger: “And you’re ugly too” | genomeboy (genetic testing/patents, brca....)



“And you’re ugly too” | genomeboy

"All of this, of course, was precipitated by AMP v. USPTO (“The Myriad Case”), in which patients with family histories of breast cancer asserted that they have not been able to get confirmatory or “second opinion” testing because there is but a single, exclusive licensee of the patents on the most clinically important genes that predispose to hereditary breast and ovarian cancer, BRCA1 and BRCA2.

I attended the public hearing at the USPTO in Alexandria, VA on 16 February 2012.  I was so appalled by what I heard that I attended the second one in San Diego on 9 March 2012 and testified. I am still adding links to my testimony in order to submit it before public comment closes on 26 March 2012. Here is a brief excerpt on Myriad’s unwillingness to share its mutation data:................"

open access: March 12th - Daily aspirin reduces colorectal cancer incidence in patients with Lynch syndrome - Barton - 2012 - CA: A Cancer Journal for Clinicians - Wiley Online Library



Daily aspirin reduces colorectal cancer incidence in patients with Lynch syndrome - Barton - 2012 - CA: A Cancer Journal for Clinicians 

"According to the investigators, this study, along with earlier data, supports the use of aspirin in the chemoprevention treatment of patients with Lynch syndrome, although the dose and timing of use have not been established. A CAPP3 study is planned that will investigate optimizing the dose and duration. (More information can be found at www.CAPP3.org.)"

AACR Announces Annual Meeting 2012 Press Conference Schedule



AACR Announces Annual Meeting 2012 Press Conference Schedule:

Bookmark and Share
PHILADELPHIA — The American Association for Cancer Research is pleased to announce the official press conference schedule for the AACR Annual Meeting 2012, held in Chicago, Ill. from March 31 – April 4.
Press conferences will be held at the Hyatt McCormick Conference Center, which is adjacent to the McCormick Place Conference Center. Attendance is limited to registered members of the media and pre-approved guests.

CMAJ: Who should hold the keys to your DNA?




Editor’s note: Third of a multipart series on genetic testing.
Part 1: Separating hype from reality in the era of the affordable genome (www.cmaj.ca/lookup/doi/10.1503/cmaj.109-4143).
Part 2: Popping the genetics bubble (www.cmaj.ca/lookup/doi/10.1503/cmaj.109-4142).
Next: Race and genetics in the doctor’s office



CMAJ: Who should hold the keys to your DNA?

"Opinion is divided over whether doctors or patients should be receiving the results of direct-to-consumer genetic tests........."

"“I think there is a need to think this through and to have some balance. On the one hand, we should respect consumers’ preferences and freedom to choose,” says Peter Neumann, director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center in Boston, Massachusetts and lead author on the paper. “We should also inform them about the risks and benefits.”
In some countries, governments have stepped in to ensure that doctors are the ones who must inform consumers about risks and benefits. Laws in France, Germany, Portugal and Switzerland stipulate that genetic tests only be administered by physicians. There are no regulations in Canada and few in the United States, though the US Food and Drug Administration has indicated that it will be stepping up efforts in the area...." 

Women of Teal: upcoming talk: speaker - Dee Sparacio (and blogger) Survivor to Survivor: Understanding Cancer Research



Monday, March 12, 2012


Survivor to Survivor: Understanding Cancer Research

I cordially invite you to attend my upcoming talk at the Cancer Support Community of Central New Jersey (3 Crossroads Drive, Bedminster, NJ).


Survivor to Survivor: Understanding Cancer Research
Thursday, March 15 • 6:30–7:30 pm
Guest Speaker: Dee Sparacio, CSC Participant, Ovarian Cancer Survivor and Research Advocate
Cure for Cancer Found–News at 11! What do the cancer research sound bites on the evening news mean for you? Learn how to read and interpret cancer research results from posters to journal articles. Find out which Web sites are reputable sources of cancer research information.
Please call 908-658-5400 to register.

Survey Reveals Pressures to Increase Volume of Colonoscopies Adversely Impacts How Gastroenterologists Perform the Screening and Could Potentially Affect Procedure Quality



Survey Reveals Pressures to Increase Volume of Colonoscopies Adversely Impacts How Gastroenterologists Perform the Screening and Could Potentially Affect Procedure Quality

OMICS Publishing Group | Full-text | Peutz-Jegher Syndrome in Gynecologic Pathology (PJS and ovarian cancer)



OMICS Publishing Group | Full-text | Peutz-Jegher Syndrome in Gynecologic Pathology

Sunday, March 11, 2012

Seth's Blog: "It's not business, it's personal"



Seth's Blog:

"It's not business, it's personal"

It's too easy to blame the organization and the system and the bottom line for decisions that a person would never be willing to take responsibility for.
Whenever you can, work with people who take it personally.

abstract: Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 (includes graphic/study of 23 patients)



 Highlights
(in study of 23 patients)

► Three new markers were compared to CA125 for lead time to ovarian cancer recurrence.
► HE4 elevates at recurrence when CA125 does not.
► Mesothelin has less marker potential, MMP7 shows promise and requires confirmation.
  
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125: Publication year: 2012

Objective 
Evaluate and compare the effectiveness of CA125, HE4, Mesothelin and MMP7 marker levels to monitor ovarian cancer patients after surgery and chemotherapy. Evaluate the lead time of a rise of marker levels before recurrence.

Methods 
The study consists of 23 patients with advanced stage ovarian/fallopian tube cancer. Blood was drawn after front line surgery and chemotherapy treatment and at 3 month intervals thereafter. One patient had chemoresistant disease, two patients remained in remission and 20 patients had recurring disease and were used for marker evaluation.

Results
In five patients HE4 was the only marker to elevate before recurrence with a lead time of up to 4½ months including one patient who did not have a CA125 response at all. In a further two patients, HE4 increased before CA125 did. In four of these seven patients, HE4 levels were consistently at or above threshold during remission when both CA125 and imaging results were negative. MMP7 elevated before recurrence in one patient who was negative for the other markers. Mesothelin elevated in two patients who were also positive for CA125 and HE4.

Conclusions 
HE4 can predict ovarian cancer recurrence earlier than CA125 and it can be elevated in patients that do not express CA125 at sufficient levels to make a clinical decision. MMP7 and Mesothelin have lower potential as markers for ovarian cancer recurrence to complement CA125. A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis.

Graphical Abstract

image

Highlights

► Three new markers were compared to CA125 for lead time to ovarian cancer recurrence.
► HE4 elevates at recurrence when CA125 does not.
► Mesothelin has less marker potential, MMP7 shows promise and requires confirmation.

repost from December 2011: A study of symptoms described by ovarian cancer survivors



A study of symptoms described by ovarian cancer survivors: Publication year: 2012

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study



A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study


Objective 
To define the maximum tolerated dose (MTD) and assess the feasibility of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in women with newly diagnosed Stages II–IV ovarian, fallopian tube, or primary peritoneal carcinoma.

Methods 
Patients received escalating doses of paclitaxel IV and carboplatin IP on day 1 and paclitaxel IP 60mg/m2 on day 8. A standard 3+3 design was used in the escalation phase. A two-stage group sequential design with 20 patients at the MTD was used in the feasibility phase. Patient-reported neurotoxicity was assessed pre and post treatment.

Results 
Patients were treated with paclitaxel 175mg/m2 IV and carboplatin IP from AUC 5–7 on day 1 and paclitaxel 60mg/m2 IP on day 8. The MTD was estimated at carboplatin AUC 6 IP and 25 patients enrolled at this dose level. Within the first 4cycles, seven (35%) of twenty evaluable patients had dose-limiting toxicities (DLTs) including grade 4 thrombocytopenia (1), grade 3 neutropenic fever (3), >2week delay due to ANC recovery (1), grade 3 LFT (1), and grade 3 infection (1). De-escalation to paclitaxel 135mg/m2 IV was given to improve the safety. After six evaluable patients completed 4 cycles without a DLT, bevacizumab was added and six evaluable patients completed 4cycles with one DLT (grade 3 hyponatremia).

Conclusions 
Paclitaxel at 175mg/m2 IV, carboplatin AUC 6 IP day 1 and paclitaxel 60mg/m2 IP day 8 yield 18–56% patients with DLTs. The tolerability of the regimen in combination with bevacizumab was indicated in a small cohort.

abstract: Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies



 Blogger's Note: the abstract does not differentiate types of gyn cancers, journal is subscriber based ($$$)

Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies

Objective 
Lymphatic ascites is an unusual complication in patients with cancer. In the gynecologic oncology patient population, the most common etiology is operative lymph node dissection. The purpose of this study was to explore the incidence, presenting symptoms, methods of diagnosis and treatment modalities utilized for lymphatic ascites in patients undergoing lymph node dissection for gynecologic cancers.

Methods 
This observational study retrospectively reviewed the charts of patients who underwent lymphadenectomy as part of the surgical management for a gynecologic cancer. Patients that developed postoperative lymphatic ascites between January 2000 and December 2010 were included for analysis. Data extracted from the medical records included tumor pathology, number of harvested lymph nodes, postoperative course, method of diagnosis and treatment.

Results
From a total of 300 surgical staging procedures, 12 patients with lymphatic ascites were identified (4%). The most common reported symptom was leakage of clear fluid per vagina (7, 58%), followed by abdominal distension (4, 33%). The median interval from surgery to development of symptoms was 12.5 days (range 0–22days). 5 patients had complete resolution of symptoms with dietary modifications alone while 7 patients required paracentesis. The median time from surgery to resolution of symptoms was 44days (range 9–99).

Conclusion 
Lymphatic ascites is an under recognized and infrequently reported postoperative complication. Although it usually resolves spontaneously or with conservative management without sequelae, this condition can significantly prolong postoperative recovery and cause patient discomfort. To our knowledge this is the largest group of patients undergoing gynecologic surgical staging procedures to be reviewed for the occurrence of lymphatic ascites.

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites



A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

Objective 
The recombinant fusion protein, aflibercept binds and neutralizes vascular endothelial growth factor (VEGF) A, B and placental growth factor (PlGF). Aflibercept inhibits ascites formation and reduces tumor burden in an ovarian cancer model. This open-label, single-arm, multicenter phase II study assessed the efficacy and safety of aflibercept in patients with advanced chemo-resistant epithelial ovarian cancer and symptomatic malignant ascites.

Methods 
Patients who required ≥3 previous paracenteses at 1-4 paracenteses per month received intravenous aflibercept 4mg/kg every 2weeks. The primary endpoint was repeat paracentesis response rate (RPRR), with response defined as at least a two-fold increase in time to repeat paracentesis compared with the baseline interval.

Results 
Ten out of 16 enrolled patients achieved a response; the RPRR was 62.5% (95% CI 35.4%–84.8%). Aflibercept was considered effective based on a hypothesis that the RPRR was ≥60%. Median time to repeat paracentesis was 76.0 (95% CI 64.0–178.0) days, which was 4.5 times longer than the baseline interval (16.8days). Median progression-free survival was 59.5 (95% CI 41.0–83.0) days. Twelve patients experienced adverse events considered related to aflibercept treatment including hypertension (7 patients), headache, anorexia, and dysphonia (3 patients each). Two patients experienced Grade 3/4 treatment-related adverse events (Grade 3 hypertension and weight loss in one patient, Grade 3 intestinal perforation in one patient).

Conclusion 
Aflibercept 4mg/kg every 2weeks was effective at controlling malignant ascites, reducing the interval between repeat paracenteses. The safety profile was consistent with that reported for anti-VEGF agents.

Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)



Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC):

Objective 
To describe the outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) so as to define the criteria for patient selection for palliative surgery. Methods 90 women with relapsed EOC underwent palliative surgery for bowel obstruction between 1992 and 2008.

Conclusion 
Surgery for bowel obstruction in relapsed EOC is associated with a high morbidity and mortality rate especially in emergency cases when compared to other gynaecological oncological procedures. Palliation can be achieved in almost two thirds of cases, is equally likely in elective and emergency cases but is less likely in those with ascites.

abstract: Have racial disparities in ovarian cancer increased over time? An analysis of SEER data



Have racial disparities in ovarian cancer increased over time? An analysis of SEER data:

Objective 
Race has been postulated to be a prognostic factor in women with ovarian cancer. The reasons for racial disparities are multifactorial. Recent literature suggests that racial disparities in ovarian cancer survival emerged in the 1980s, when modern treatments such as aggressive surgical debulking and platinum-based chemotherapy first gained widespread use. We suspect that as improvements in treatment have evolved, the effects of access to treatment have amplified racial disparities in survival from ovarian cancer. Methods SEER 9 data were analyzed, including African American and white patients diagnosed with ovarian cancer from 1973 to 2007, with 2008 as the cutoff for follow-up. Using the Kaplan–Meier method, we evaluated racial differences in survival, to determine whether this difference has increased over time.

Results
There were 44,562 white and 3190 African American women available for analysis. Overall African Americans had 1.10 times the crude hazard (95% CI 1.06–1.15) of all-cause mortality compared to whites, with a widening trend over time (p<0.01). Adjusted for SEER registry, age, tumor stage, marital status and time of diagnosis, the hazard ratio (HR) for all-cause mortality comparing African Americans to whites was 1.31 (95% CI 1.26–1.37). When the receipt of surgery was added to the model, the HR for all-cause mortality remained higher for African American women at 1.27 (95% CI 1.21–1.34).

Conclusions 
African Americans diagnosed with ovarian cancer have worse survival than whites, and this disparity has increased over time. Measured differences in treatment, such as receipt of surgery, account for part of the disparity.

Disparities in hospice care among older women (over 65 yrs) dying with ovarian cancer



Disparities in hospice care among older women dying with ovarian cancer:

Background
Timely hospice referral is an essential component of quality end-of-life care, although a growing body of research suggests that for patients with various types of cancer, hospice referrals often occur very late in the course of care, and are marked by sociodemographic disparities. However, little is known about the ovarian cancer patient population specifically. We examined the extent and timing of hospice referrals in ovarian cancer patients over age 65, and the factors associated with these outcomes.

Methods
We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify 8211 women aged 66+ with ovarian cancer who were diagnosed between 2001 and 2005 and died by December 31, 2007. We excluded women who were not eligible for Medicare A continuously during the 6 months prior to death. Outcomes studied included overall hospice use in the last 6months of life and late hospice enrollment, defined as within 3 days of death. We examined variations in these two measures based on year of diagnosis and sociodemographic characteristics (age, race, marital status, rural residence, income, education) and type of Medicare received (fee-for-service vs. managed care).

Results 
Among 8211 women in the cohort who died from ovarian cancer, 39.7% never received hospice care (3257/8211). Overall hospice care increased over the period of observation, from 49.7% in 2001 to 74.9% in 2005, but the proportion of women receiving hospice care within 3days of death did not improve. Among those who received hospice care, 11.2% (556/4954) and 26.2% (1299/4954) received such care within 3 and 7 days of death, respectively. A higher proportion of black women (46.5% vs. 38.4% among whites), women in the lowest income group (42.8% vs. 37.0% in the highest income group), and those receiving fee-for-service Medicare (41.3% vs.33.5% for women in managed care) never received hospice care. In multivariable models, factors associated with lack of hospice care included age younger than 80 years (OR 1.27, 95% CI 1.15–1.40), non-white race (OR 1.44, 95% CI 1.26–1.65), low income (OR 1.17, 95% CI 1.04–1.32) and enrollment in fee-for-service Medicare compared with managed care (OR 1.39, 95% CI 1.24–1.56).

Conclusion 
More older women with ovarian cancer are receiving hospice care over time, however, a substantial proportion receive such care very near death, and sociodemographic disparities in hospice care exist. Our data also support the need to target lower-income and minority women in efforts to increase optimally timed hospice referrals in this population. Our finding that ovarian cancer patients enrolled in managed care plans were more likely to receive hospice care suggests the importance of health care system factors in the utilization of hospice services.

abstract: Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma 10.1016/j.canlet.2011.12.035 : Cancer Letters | ScienceDirect.com



Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma 10.1016/j.canlet.2011.12.035 : Cancer Letters | ScienceDirect.com

 Abstract

The adhesion molecule L1CAM (CD171) accounts for enhanced motility, invasiveness and chemoresistance of tumor cells and represents a novel marker for various tumor entities including pancreatic and ovarian carcinoma. Recently, we showed that L1CAM inhibition increases the apoptotic response of tumor cells towards cytostatic drugs pointing to the potential of L1CAM to serve as a chemosensitizer in anti-cancer therapy. Thus, the present study evaluated the therapeutic potential of combined treatment with L1CAM antibodies and chemotherapeutic drugs in pancreatic and ovarian carcinoma model systems in vivo.

Saturday, March 10, 2012

open access: Adequacy of family history taking in ovarian cancer patients: a population-based study.



Blogger's Note: repost/open access

Adequacy of family history taking in ovarian cancer patients: a population-based study

Abstract:
The aim of this study was to evaluate the adequacy of family history taking in epithelial ovarian cancer (EOC) patients and to identify factors that determine adequacy. Furthermore, the validity of family history taking was assessed by comparison with self-administered questionnaires. Medical records of all 1,112 EOC patients registered by the nation-wide cancer registry and diagnosed in eleven Dutch hospitals between 1996 and 2006 were reviewed. Adequate family history taking was defined as a written notification of the presence or absence of relatives with breast or ovarian cancer. Factors that were correlated with family history taking were identified using univariable and multivariable logistic regression. 147 patients filled in a postal questionnaire. An adequate family history was taken in 41% of all cases. Younger age, an academic hospital and having undergone surgery and/or chemotherapy were associated with adequate family history taking. The comparison with self-administered questionnaires showed a disagreement in 64% mainly due to missing data in medical records. Documentation on family history is either absent or inadequate in the medical records in the majority of EOC patients. These data urge for better uptake of hereditary cancer risk assessment. Different strategies for this assessment like improved family history taking and genetic testing in EOC patients should be explored.

Why the Web Lacks Authoritative Reviews of Doctors - NYTimes.com



Why the Web Lacks Authoritative Reviews of Doctors - NYTimes.com

New Silicone Breast Implant Approved by FDA



New Silicone Breast Implant Approved by FDA

Recurrent germline mutations in BRCA... [Breast Cancer Res Treat. 2012] - PubMed - NCBI



Recurrent germline mutations in BRCA... [Breast Cancer Res Treat. 2012] - PubMed - NCBI
 Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.


Abstract

The spectrum of germline mutations among Jewish non Ashkenazi high risk breast/ovarian cancer families includes a few predominant mutations in BRCA1 (185delAG and Tyr978X) and BRCA2 (8765delAG). A few additional recurring mutations [A1708E, 981delAT, C61G (BRCA1) R2336P, and IVS2 + 1G > A (BRCA2)] have been reported in Jewish non Ashkenazi families. The 4153delA*BRCA1 C61G*BRCA1 and the 4075delGT*BRCA2 has been reported to recur in Russian/Polish non Jews and Ashkenazim, respectively. The rate of these recurring mutations has not been reported in Israeli high risk families. Genotyping for these recurring mutations by restriction enzyme digest and sequencing method was applied to high risk, predominantly cancer affected, unrelated Israeli individuals of Ashkenazi (n = 827), non Ashkenazi (n = 2,777), non Jewish Caucasians (n = 193), and 395 of mixed ethnicity. Jewish participants included 827 Ashkenazi, 804 Balkans, 847 North Africans, 234 Yemenites, and 892 Asians (Iraq and Iran). Age at diagnosis of breast cancer (median ± SD) (n = 2,484) was 47.2 ± 9.6 for all women participants. Males (n = 236) were also included, of whom 24 had breast cancer and 35 had pancreatic cancer. Overall, 8/282 (2.8%) of the Balkan cases carried the BRCA1*A1708E mutation, 4/180 (2.2%) the R2336P mutation, and 0/270 the IVS2 + 1G > A BRCA2 mutations, respectively. Of North Africans, 7/264 (2.65%) carried the BRCA1*981delAT mutation. The BRCA1*C61G mutation was detected in 3/269 Ashkenazi, non Ashkenazi, and non Jewish Russians; the BRCA1*Tyr978X mutation was detected in 23/3220 individuals of non Ashkenazi origin, exclusively of Asian ethnicity (23/892, 2.6% of the Asians tested). The BRCA1*4153delA mutation was noted in 2/285 non Jewish Caucasians, and none of the Ashkenazim (n = 500) carried the BRCA2*4075delGT mutation. Jewish high risk families of North African, Asian, and Balkan descent should be screened for the 981delAT, Tyr978X, A1708E BRCA1, and the R2336P BRCA2 mutations, respectively.